Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ayoub
Amal Ayoub, Be'Er Sheva IL
| Patent application number | Description | Published |
|---|---|---|
| 20100099940 | Thulium-containing low dose rate brachytherapy seed - A low dose rate brachytherapy seed having activity in the range between 0.5 and 10 millicurie, preferably less than 3 millicurie, comprising thulium-170 placed within a casing and at least one layer of a radiation emission modifying metal, said layer being provided either internally within the casing or on the outer surface thereof. The radiation emission modifying metal is preferably gold. | 04-22-2010 |
Khalil Ayoub, Kanata CA
| Patent application number | Description | Published |
|---|---|---|
| 20120005211 | DOCUMENT OBJECT MODEL (DOM) BASED PAGE UNIQUENESS DETECTION - DOM based unique ID generation, including receiving a hypertext markup language (HTML) page at a computer, and identifying HTML page elements in response to the receiving, the HTML page elements comprising parent nodes, the parent nodes comprising child nodes. The method further comprising processing each of the HTML page elements, the processing comprising: grouping the child nodes by parent node into a group of child nodes, detecting patterns in the group of child nodes in response to the grouping, reducing the group of child nodes to text strings in response to the detecting, storing the text strings as text values in the parent nodes, and generating a unique identifier (ID) of the HTML page in response to the processing. | 01-05-2012 |
Mimoun Ayoub, Otelfingen CH
| Patent application number | Description | Published |
|---|---|---|
| 20120027805 | Controlled-Released Peptide Formulations - Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent. | 02-02-2012 |
Mohamed Ayoub, Durham GB
| Patent application number | Description | Published |
|---|---|---|
| 20120045868 | SEMICONDUCTOR DEVICE CONTACTS - A method of fabrication of electrical contact structures on a semiconductor material is described comprising the steps of: depositing an oxide of a desired contact material by a chemical electroless process on a face of the semiconductor material; and reducing the oxide via a chemical electroless process to produce a contact of the desired contact material. A method of fabrication of a semiconductor device incorporating such electrical contact structures and a semiconductor device incorporating such electrical contact structures are also described. | 02-23-2012 |
Nabieh Ayoub, Hills Road GB
| Patent application number | Description | Published |
|---|---|---|
| 20090253144 | METHODS OF ASSESSING DNA DAMAGE - This invention relates to the finding that HP1β is phosphorylated at Thr51 at an early stage in the DNA damage response in cells. Thr51P HP1β is therefore a biomarker for DNA damage which may be useful, for example, in assessing DNA damage, cancer susceptibility or the responsiveness of an individual to DNA damaging therapies. | 10-08-2009 |
Paul Marie Ayoub, Amsterdam NL
| Patent application number | Description | Published |
|---|---|---|
| 20100217038 | PROCESS FOR CONVERTING LEVULINIC ACID INTO PENTANOIC ACID - A process for converting levulinic acid into pentanoic acid, the process comprising the following steps: (a) contacting a feedstock comprising levulinic acid under hydrogenating conditions, in the presence of hydrogen, with a non-acidic heterogeneous hydrogenation catalyst comprising a hydrogenation metal supported on a solid catalyst carrier to obtain a first effluent comprising gamma valerolactone; (b) contacting at least part of the first effluent under hydrogenating conditions, in the presence of hydrogen, with a strongly acidic catalyst and a hydrogenation metal to obtain a second effluent comprising pentanoic acid, wherein step (b) is operated at a conversion per pass of at most 70 wt % to obtain the second effluent comprising pentanoic acid and unconverted gamma valerolactone, and wherein part of the unconverted gamma valerolactone is recycled to step (a) and/or step (b). | 08-26-2010 |